NCT03963167View on ClinicalTrials.gov

Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)

CompletedOBSERVATIONAL

Enrollment

661

Participants

Timeline

Start Date

August 21, 2019

Primary Completion Date

March 4, 2022

Study Completion Date

March 4, 2022

Conditions

COPD

Interventions

DRUG

BDP/FF/G fixed combination

Fixed combination of Inhaled Corticosteroid (ICS) / Long-acting β2-agonist (LABA) / long-acting muscarinic antagonist (LAMA) that contains Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (G).

Trial Locations (1)

Unknown

Fondazione Policlinico Gemelli, Rome

All Listed Sponsors

lead

Chiesi Italia

INDUSTRY

NCT03963167 - Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL) | Biotech Hunter | Biotech Hunter